Safety and efficacy profile of first-in-class oral p53 reactivator rezatapopt
1. In this phase 1-2 single-group trial, the p53 reactivator rezatapopt was well-tolerated in adults with solid tumors harboring the ...
1. In this phase 1-2 single-group trial, the p53 reactivator rezatapopt was well-tolerated in adults with solid tumors harboring the ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.